Oxford, UK - 1 October 2019: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, today announces that on 30 September 2019, Jonathan Emms, Chief Operating Officer of Circassia, purchased 300,000 Ordinary Shares on the London Stock Exchange at a price of 16.5 pence per share.
Steve Harris, Chief Executive Officer
Julien Cotta, Chief Financial Officer
Rob Budge, Corporate Communications
Tel: +44 (0)1865 405560
Peel Hunt (Nominated Adviser and Joint Broker)
James Steel / Dr Christopher Golden
Tel: +44 (0) 20 7418 8900
finnCap (Joint Broker)
Geoff Nash / Alice Lane
Tel: +44 (0) 20 7220 0500
Numis Securities (Joint Broker)
James Black / Freddie Barnfield
Tel: +44 (0) 20 7260 1000
Simon Conway / Ciara Martin
Tel: +44 (0) 20 3727 1000
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities / person closely associated
Reason for the notification
Chief Operating Officer
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Circassia Pharmaceuticals plc
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the
Financial instrument, type of instrument
Ordinary Shares of 0.08p each
Nature of the transaction
Purchase of Ordinary Shares
Price(s) and volume(s)
· Aggregated volume
Date of the transaction
Place of the transaction
London Stock Exchange, AIM
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows.
Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...